



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/037,299	10/25/2001	Stewart Thomas Leslie	208.1009	4506
23280	7590	05/12/2008		
Davidson, Davidson & Kappel, LLC			EXAMINER	
485 7th Avenue			YOUNG, MICAH PAUL	
14th Floor			ART UNIT	PAPER NUMBER
New York, NY 10018			1618	
		MAIL DATE	DELIVERY MODE	
		05/12/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/037,299	<b>Applicant(s)</b> LESLIE, STEWART THOMAS
	<b>Examiner</b> MICAH-PAUL YOUNG	<b>Art Unit</b> 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(o).

#### Status

- 1) Responsive to communication(s) filed on 11 February 2008.  
 2a) This action is FINAL.      2b) This action is non-final.  
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1,2 and 5-19 is/are pending in the application.  
 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.  
 5) Claim(s) \_\_\_\_\_ is/are allowed.  
 6) Claim(s) 1,2 and 5-19 is/are rejected.  
 7) Claim(s) \_\_\_\_\_ is/are objected to.  
 8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.  
 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
 a) All    b) Some \* c) None of:  
 1. Certified copies of the priority documents have been received.  
 2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)                                  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date: _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                         | 5) <input type="checkbox"/> Notice of Informal Patent Application                       |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-146/08)<br>Paper No(s)/Mail Date: _____ | 6) <input type="checkbox"/> Other: _____  |

## DETAILED ACTION

**Acknowledgment of Papers Received:** Response dated 2/11/08.

### *Claim Rejections - 35 USC § 102*

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless —

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 2, 5-13 and 16 are rejected under 35 U.S.C. 102(b) as being anticipated by

Granger et al (USPN 5,149,538 hereafter '538). The claims are drawn to a transdermal formulation comprising an opioid analgesic and a distressing substance.

The '538 patent teaches a transdermal dosage form that is formulated to be resistant to abuse (See Abstract). The dosage form may comprise an opioid, such as buprenorphine (See Column 4, Lines 36). An opioid antagonist such as naloxone is also included to prevent misuse of the dosage form (See Column 5, Lines 26-38). The antagonist is released from the dosage form when it is ingested or immersed in a solvent (See Column 2, Lines 40-46). A variety of permeation enhancers may be incorporated into the dosage form (See Column 4, Line 63 to Column 5, Line 25). Various embodiments of the disclosed invention include the use of an adhesive matrix containing the opioid; the use of a barrier means to separate the antagonist from the opioid, and the use of a soluble material that encapsulates discrete units of the antagonist (See Column 4, Lines 11-27; and Column 6, Lines 3-19). These disclosures render the claims anticipated.

### *Claim Rejections - 35 USC § 103*

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Claims 1, 2, 5-13 and 15-19 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures Granger et al (USPN 5,149,538 hereafter '538) in view of Blum et al (USPN 5,891,919 hereafter '919), Porter (USPN 4,175,119 hereafter '119). The claims are drawn to a transdermal formulation comprising an opioid analgesic such as buprenorphine and distressing agents such as an ergolide, bitter quaternary ammonium compounds or an emetic compound.

As discussed above the '538 patent discloses a transdermal formulation comprising opioid analgesics and distressing agents, the reference is however silent to the specific, emetic or bitters compounds of the instant claims. These compounds are well known in the art for their distressing properties and it would have been obvious to include them into the abuse deterring formulation of the '538 patent. The compounds are found in the '919, '550 and '119 patents.

The '919 patent discloses a formulation comprising denatonium capsaicinate as a substance providing a bitter and/or spicy flavor for use as an aversive agent (Abstract). It may be incorporated into topical formulation and dressings and other pharmacological compositions (See Column 4, Lines 38-47). It would have been obvious to include the compound into the '538 formulation since this reference establishes the compounds use in aversion technologies.

The '119 patent discloses the use of an emetic to prevent accidental or intentional overdose of a psychoactive substance (Abstract, Column 1, lines 40-43). Such emetic substances include emetine hydrochloride, ipecamine, hydro-ipecamine and ipecacuanhin acid (Column 1, lines 52-57). It may be incorporated into formulation containing narcotic analgesics such as hydromorphone and codeine (Column 3, Lines 55-57). It would have been obvious to include the emetics into the '538 patent since both reference disclose the control of misusing the same compounds.

It would have been obvious to combine the bitter and emetic compounds of the '919 and '119 patents in order to provide a sufficient deterrent to potential misuse. The '538 patent discloses a transdermal formulation comprising opioid analgesics along with compounds that prevent abuse by ingestion or solvent extraction. These compounds included nauseants such as naloxone. The reference establishes the level of skill in the art regarding the inclusion of nauseants and distressing compounds into potential abusive compositions. The bitter/spicy flavoring compounds of the '919 would cause distress if applied directly, and the emetics of the '119 would cause nausea upon exposure. It would have been obvious to combine the compounds in the transdermal formulation of the '538 with an expected result of a transdermal formulation useful in deterring misuse.

Claims 1, 10, 14 and 15 are rejected under 35 U.S.C. 103(a) as being unpatentable over the combined disclosures of Granger et al (USPN 5,149,538 hereafter '538) in view of Yum et al (USPN 6,001,390 hereafter '390) and Drugs: Facts and Comparisons, entry for *Pergolide Mesylate* pages 1621-1624.

As discussed above the '538 patent discloses a transdermal formulation comprising opioid analgesics and distressing agents, the reference is however silent to the specific ergolide, emetic or bitters compounds of the instant claims. These compounds are well known in the art for their distressing properties and it would have been obvious to include them into the abuse deterring formulation of the '538 patent. The compounds are found in the '390 patent.

The '390 patent a transdermal formulation comprising pergolide salts (abstract). The pergolides do not readily permeate through the skin and require permeation enhancers (col. 4, lin. 47-65). It would have been obvious to include the pergolide into the transdermal formulation of the '538 since they are similar formulations with similar components.

According to the *Pergolide* entry in the Drug textbook, the most common adverse reactions include nausea, dyskinesia, somnolence and rhinitis (page 1622). An artisan of ordinary skill would have been motivated to include the pergolide into the transdermal formulation of the '538 patent since the common side effects would negatively impact a user upon misuse. Since the pergolides would not be permeable through the skin, they would act to deter misuse through injection or solvent distillation.

With these things in mind it would have been obvious include the ergot compounds of the '390 patent into the misuse deterring transdermal formulation of the '538 patent in order to provide sufficient deterrents to misuse. The side effects of pergolide salts are well known in the

art as shown in the Drug textbook, and would have been an obvious addition to an aversion formulation. It would have been obvious to combine the teachings and formulations with an expected result of a transdermal formulation useful in treating pain without leading to potential abuse.

*Response to Arguments*

Applicant's arguments with respect to claims 1, 2, and 5-19 have been considered but are moot in view of the new ground(s) of rejection.

However regarding the Granger, and Blum patents, it remains the position of the Examiner that this combination would continue to obviate the claims. Applicant argues that since the purpose of the opioid antagonist in the Granger patent is to attenuate the euphoric effect so of the opioid there would be no motivation to include the bitter/spicy, and caustic repellent compounds of the Blum patent. However if the purpose of the antagonist is to simply attenuate the euphoric properties of the opioid analgesics, this could be achieved by adding bitter/spicy and otherwise caustics compounds to the formulation. These distressing and caustic compounds would severely reduce the euphoric effects of any opioid compound associated with it. The compounds of the Blum patent are bitter to the taste and spicy. These would cause burning sensations and have an unpleasant smell and taste. What better way to reduce an opioid's euphoric effects than causing unwanted burning, and nausea do to bitter taste and capsaicinate burning. For these reasons the claims remain obviated.

Regarding the combination of the Granger and Porter patents, it remains the position of the Examiner that the combination would continue to obviate the claims. The Porter patent establishes that emetic compounds are used to reduce misuse of opioid compounds via negative

side effect. The patent establishes that the emetic compounds should not be admixed with the opioid and kept separate from the opioid analgesic. The transdermal patch of Granger patent keeps the opioids and antagonist separated and not admixed together. The antagonist are separated by a barrier layer or encapsulated by barrier means, and not admixed or commingled with the opioid analgesics. Since the purpose of the antagonist is to attenuate the effects of the opioid analgesic, the inclusion of emetic compounds as shown in the Porter patent would have been an obvious addition since emesis is an undesirable effect on the body. For these reasons the claims remains obviated.

*Correspondence*

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICAH-PAUL YOUNG whose telephone number is (571)272-0608. The examiner can normally be reached on Monday-Friday 7:00-4:30; every other Monday off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michael G. Hartley/  
Supervisory Patent Examiner, Art Unit 1618

/MICAH-PAUL YOUNG/  
Examiner, Art Unit 1618